Archives of Cancer Biology and Therapy

Short Communication Open Access

VA-Radiation Oncology Quality Surveillance Program: Enhancing Quality Measure Data Capture, Measuring Quality Benchmarks and Ensuring Long Term Sustainability of Quality Improvements in Community Care

Evangelia Katsoulakis, Rishabh Kapoor, John Park, Christina Chapman, Abhi Solanki, Lindsay Puckett, Rebecca Hagan, William Sleeman, Jatinder Palta, Michael Hagan

High quality cancer care improves patient survival and quality of life. Radiation plays an important role in cancer management, given that over 50% of all cancer patients receive radiation therapy as either a primary treatment or for palliation. Ensuring quality of radiotherapy specifically, is therefore important to achieving optimal patient outcomes.

Commentary Open Access

Reduced BCR Signaling and a Metabolic Shift Accompanies Malignant Progression of Follicular Lymphoma: A Lesson from Transcriptomics

Cesare Sala, Annarosa Arcangeli

Lymphoma represents the most common form of hematological malignancy in the developed world, accounting for 3.6% of all cancers and 55.6% of all blood cancers in Europe, with non-Hodgkin lymphomas (NHL) representing 90% of cases.

Commentary Open Access

The Challenge of Cognitive Dissonance in the Delivery of Precision Medicine in Veterinary Oncology

J. Cawley, C. Khanna

The use of molecular and genomic analysis of a cancer as a means to define a patient-specific treatment is interchangeably referred to as Precision Medicine, Personalized Medicine, or Genomically-directed medicine (herein, collectively PMED).

Short Communication Open Access

Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP₅₃-Mutated Cancers

Shaoli Das, Xiang Deng, Kevin Camphause, Uma Shankavaram

Tumors harboring mutations in certain oncogenes are often dependent on activation of certain pathways which becomes essential for the survival of the cancer cells. This condition is formally known as synthetic lethality, a state when simultaneous loss of two genes is lethal to a cancer cell, while the loss of the individual genes is not.

Short Communication Open Access

Prognosis and Survival of Medullary Carcinoma of the Breast

Alberto Piamo Morales, García Rojas Mayra

Medullary breast carcinoma (MBC) is a rare tumor, representing 3% to 5% of invasive breast carcinomas. The World Health Organization defines it as a well-circumscribed invasive tumor, composed of poorly differentiated cells, arranged in sheets, without gland formation and a scarce collagen stroma with the presence of a very prominent lymphoplasmacytic infiltrate.